USPTO serial 79213643
PROSILIC
Reviewed by CopyMark Law Group
Reg. 5614010Status 706Registered
- Filing date
- Status date
- Registration date
- Nov 27, 2018
- Examiner
- CARROLL, DORITT
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with PROSILIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Craine, Dean A
1691 e Mason Lk Drive EGrapeview, WA 98456United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for use in industry; chemical preparations for scientific purposes; biochemical substances and biochemical preparations for use in industry, science and research, namely, excipients for use in the manufacture of pharmaceutical preparations, cosmetic preparations, nutraceutical preparations, veterinary preparations, dietary supplements, foods and beverages and pharmaceutical preparations for topical use; reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; silicon for use in industry, science and research; pure non-metallic silicon sold in nanoparticle form for use in industry, science and research; pure non-metallic porous silicon sold in nanoparticle form for use in industry, science and research; silicon for use in stabilising of enzymes of chemical, biochemical and biological substances for use in industry and for scientific research purposes | ACTIVE | — |
| 005 | Chemicals and chemical preparations, namely, antiviral pharmaceutical preparations, anti-infective pharmaceutical preparations, anti-inflammatory pharmaceutical preparations, antiseptic pharmaceutical preparations, antibacterial pharmaceutical preparations, antibiotic pharmaceutical preparations; antifungal pharmaceutical preparations, anti-fibrotic pharmaceutical preparations; chemicals and chemical preparations, namely, pharmaceutical preparation for skin care; chemicals and chemical preparations, namely, pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, inflammatory diseases and disorders, respiratory and pulmonary diseases and disorders, immune system related diseases and disorders, hematological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, gastro-intestinal diseases, eye diseases and conditions, heart rhythm disorders, kidney and nephropathic diseases, hematological disorders, diabetes, hypertension, skin disorders, damaged skin and tissue, [ winkles ] * wrinkles *, wounds and allergies, insect bites, dermatological diseases and disorders, HIV, cancer and tumors, bone diseases, arthritis, cardiopulmonary, infectious diseases, blood disorders, pain, sepsis, alopecia, obesity, cognitive disorders diseases, neurological disorders, hormonal disorders, disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals skin care preparations; drug delivery agents in the form of powders, liquids and gels that provide controlled release of the active ingredients for a wide variety of pharmaceutical, nutraceutical and veterinary products | SECTION 7(e) - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 18, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 15, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 15, 2026 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Apr 9, 2026 | PCGR | PETITION TO DIRECTOR GRANTED | — |
| Mar 25, 2026 | APET | ASSIGNED TO PETITION STAFF | — |
| Oct 21, 2025 | TPDR | TEAS PETITION TO DIRECTOR RECEIVED | — |
| Sep 18, 2025 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Sep 18, 2025 | NCP7 | NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED | — |
| Sep 18, 2025 | C7P. | CANCELLED SEC. 7 - PARTIAL | — |
| Sep 9, 2025 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Sep 3, 2025 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| May 28, 2025 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| May 27, 2025 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Mar 10, 2025 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Mar 10, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 14, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Nov 27, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 30, 2020 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Jan 6, 2020 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 25, 2019 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Apr 24, 2019 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 4, 2019 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Mar 29, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 7, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 7, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 28, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 14, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 27, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 11, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 11, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 7, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 22, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 22, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 22, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 6, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 6, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 6, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 6, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 6, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 28, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 28, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 28, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 12, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 12, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 12, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 15, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 15, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2018 | ALIE | ASSIGNED TO LIE | — |
| Feb 7, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 25, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 11, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 10, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 10, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 9, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 8, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 7, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 3, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |